|
Disclaimer: The following information is drawn from materials prepared
by candidates for promotion to full professor. It is intended to illustrate activities and materials that
might support promotion. In
using these materials, please note the following:
*The Provost (and, in some cases, the President) are the University
officers authorized to approve promotions. All levels of review below these officers are advisory.
*Only Departments are empowered to propose promotions, and the
Divisional Dean is charged with transmitting such proposals to the Provost or
returning them to the Department. *The judgment of the Department, Dean, and
Provost will therefore be critical to assessing qualification for promotion.
*Materials considered by the Department, Dean, and Provost will also
(and always) include confidential evaluations obtained from outside the
University. Materials considered
by the Provost will include the confidential evaluations of the Dean and
Department, and those considered by the Dean will include the confidential
evaluations of the Department.
*Thus, the following materials are ONLY PART of a complete proposal
for promotion, whereas promotion is based on the ENTIRE proposal. Therefore, it should not be
assumed that a record comparable to that below will necessarily result in
promotion, or that a record not comparable to that below will fail to result
in promotion. The Departmental
Chair is likely to be the best source of advice as to whether promotion is
feasible and, when it is not, what additional activity may result in
qualification for promotion.
*This document has been prepared as a tool for use by associate
professors in the Division of the Biological Sciences. Other individuals who may find it informative
are Department Chairmen, Section Heads, Committee Chairmen, senior faculty
and potential recruits. Its
intent is to help guide individuals and their departments as they think about
promotion to Professor. This
document is not intended to list the elements that every promotion proposal
will be expected to address. The
following information is presented for information purposes only and is not
intended to create any contract or agreement, and its contents are subject to
addition, deletion, and change without prior notice. |
||
|
Name: |
Elaine M. Worcester, M.D. |
|
|
|
Department of Primary Appointment: |
Medicine |
|
Present rank:
|
Associate Professor |
|
Present track:
|
Clinician-Educator |
|
Proposed rank: |
PROFESSOR |
|
Proposed track: |
CLINICIAN-EDUCATOR |
DEPARTMENT: What is the candidate's field or specialization
within medicine
|
Pathophysiology,
evaluation and management of kidney stones |
LAY SUMMARY:
|
Clinical: Dr. Worcester was the medical director of the
hospital-owned Lake Park Hemodialysis Unit from September 2000 until June
2006, responsible for the care of the 110-120 patients receiving their
dialysis treatments there. She provided all direct medical care for the
patients until joined by Dr. Bharathi Reddy in July 2003, who assumed direct
care for half the patients. The medical director is also responsible for
oversight of care by all practitioners at the unit, and compliance with CMS
guidelines, including regular review of standing orders, care plans,
vaccination status, infection control, and dialyzer reuse. Dr. Worcester has had approximately 8
weeks per year of responsibility for Nephrology inpatient services, including
both the dialysis and consult services. In addition, she has one half day
outpatient clinic each week. In July 2003, she joined Drs. Fredric Coe and
John Asplin as a part of the Kidney Stone Program, and sees both kidney stone
and general nephrology outpatients. Educational: Dr. Worcester has supervised nephrology
fellows during their rotations in the dialysis units, where first year
fellows spend 2 months, and second year fellows care for a shift of patients
for the entire year, and teaches fellows and residents rotating on the
Nephrology inpatient services. She gives lectures as part of the Nephrology
FellowÕs lecture series and also the Nephrology portion of the Clinical
Pathophysiology course for second year medical students. She is director of
the Essentials of Patient-Oriented Research Course, a weekly lecture series
during the fall, winter and spring quarters, which is a part of the K30
Clinical Research Training Program. Administrative: Dr. Worcester was director of Chronic
Hemodialysis from July 2001-June 2006, overseeing the three outpatient
hemodialysis units owned by the University, which care for about 400
patients. She is currently Clinical Director of the Kidney Stone Evaluation
Laboratory, a CAP-approved lab located within the Nephrology Section. Research: Dr. Worcester is involved in clinical research
on the pathophysiology of kidney stones. This includes an on-going General
Clinical Research Center (GCRC) protocol investigating mineral excretion in
hypercalciuric stone formers, analysis of clinical data accumulated over the
30 years of the Kidney Stone Program, and development of a new rodent model
of stone formation. |
CURRICULUM VITAE
|
Society
Memberships: 1984-present International Society of
Nephrology 1984-present American Society of Nephrology
Session Organizer and Co-chair, Annual Scientific Meetings 2000, 2004
Abstract Reviewer, Annual Scientific Meetings 2003, 2005 1986-present National Kidney Foundation 1992-1994 American
Federation for Clinical Research;
Council Member, Midwest Section 2001-present Renal Physicians Association 2001-2006 National
Renal Administrators Association
1990--present ROCK (Research on Calculus Kinetics)
Society (elected) 2003-present Women in Nephrology 2006-present American Physiological Society Community
Advisory Committees and/or Activities: 1991-95 Board
Member, National Kidney Foundation of WI 1991-92 Vice
President, Milwaukee Chapter, National Kidney Foundation of WI 1992-93 President,
Milwaukee Chapter, National Kidney Foundation of WI 1993-96 Member,
Affiliate Board of Directors, National Kidney Foundation of WI 2002-2005 Member,
Medical Review Board, End Stage Renal Disease Network 9 &
10 (elected). The Renal Networks, under the direction of CMS, are
responsible
for overseeing the quality of care and access
to services of ESRD patients in their region. Network 9/10 serves
Illinois, Indiana, Ohio, and Kentucky. National
Committees and Study Sections: 1/1993
ÒPrevention and Dissolution of Renal StonesÓ. NIH Ad Hoc Review
Committee, Washington, D.C. 2/1993
NIH Site Visit Review Committee, Program Project Grant, University of
Texas Southwestern Medical Center, Dallas, Texas. 2/1996 Member,
Special Review Committee, National Institute of Diabetes and Digestive and
Kidney Diseases 10/2000 Session
Organizer and Co-Chair: ÒNephrolithiasis: Key Pathogenetic and Clinical
Issues in 2000Ó, American Society of Nephrology, Toronto 2003
American Society of Nephrology Annual Meeting Abstract Reviewer, Stone
Disease 12/2003 Invited
participant, Conference on the Medical Evaluation of the Living Renal Donor,
Dallas, TX. 10/2004 Session
Organizer and Co-Chair: ÒCell Biology of NephrolithiasisÓ, American Society
of Nephrology, St. Louis, MO. 2005
American Society of Nephrology Annual Meeting Abstract Reviewer, Stone
Disease 3/2006 Member of
Planning Committee and Invited Speaker for NIH Urolithiasis Workshop, March
9-10, 2006, Baltimore, MD.
This meeting was organized to bring together the leading investigators
in the field of urolithiasis research, in order to produce recommendations
about the most important areas for future research. 6/26/2006 Invited Member,
NIH Urology and Kidney Development and Genitourinary Diseases Study Section,
Renal and Urological Studies Review Group 2006-present Data and Safety Monitoring Board, STONE Study,
National Institute of Diabetes and Digestive and Kidney Diseases, NIH 10/2006 Invited
Member, NIH Renal and Urological Studies Scientific Review Group 2/13/2007 Invited Member, NIH
Urology and Kidney Development and Genitourinary Diseases Study Section,
Renal and Urological Studies Review Group Editorial: Reviewer for: Kidney
International American
Journal of Physiology (Renal, Fluid and Electrolyte Physiology) Journal
of Urology Journal
of the American Society of Nephrology Clinical
and Experimental Hypertension International
Society for the Study of Hypertension in Pregnancy Calcified
Tissue International Clinical
Chemistry Urological
Research Contributor
– UpToDate in Nephrology 2006- Ad hoc reviewer
– The Oxalosis and Hyperoxaluria Foundation 2004, 2006 |
PRESENTATIONS
|
Invited Lectures: 7/87 ÒGlycoprotein
Inhibitors of Calcium Oxalate Stone FormationÓ. Presented at the 10thInternational
Congress of Nephrology, London, UK. 8/88 ÒRenal
Calculi: Diagnosis and TherapyÓ and ÒAbnormalities of Divalent Ion
MetabolismÓ. Eighth Comprehensive Nephrology Review Course, UCLA Extension,
Santa Monica, CA. 8/89 ÒRenal
Calculi: Evaluation and ManagementÓ. Medical Case Conference, St. JosephÕs
Hospital, Milwaukee, WI. 1/92 ÒAdvances
in the Understanding of Crystal Formation Inhibitors in the UrineÓ Grand
Rounds, Waukesha Memorial Hospital, Waukesha, WI. 3/92 ÒProgression
of Renal Disease: Diet and HypertensionÓ. Invited speaker, American
Nephrology Nurses Association, Green Bay, WI. 3/92 ÒManagement
of Kidney Stone DiseaseÓ. Invited panelist, American College of Physicians
Annual Session, San Diego, CA. 4/93 ÒManagement
of Kidney Stone DiseaseÓ. Invited Panelist, American College of Physicians
Annual Session, Washington, D.C.. 8/93 ÒKidney
Stones: An Ounce of PreventionÓ. Grand Rounds, Columbia Hospital, Milwaukee,
WI. 4/94 ÒUrinary
Calcium Oxalate Crystal Growth InhibitorsÓ. Presented at the Jacob Lemann,
Jr. M.D. Scientific Symposium & Fetschrift, Froedert Memorial Lutheran
Hospital, Milwaukee, WI. 9/94 ÒRenal
Stones: Causes and PreventionÓ. Invited speaker, Memorial Hospital Clinical
Symposium, Woodstock, IL. 10/94
ÒOsteopontin Production by Cultured Kidney CellsÓ. Invited speaker at the New
York Academy of Sciences Conference. ÒOsteopontin; Role in Cell Signaling and
AdhesionÓ, New Brunswick, NJ. 10/94
ÒCurrent Treatment of Hypercalcemia and Disorders of Divalent IonsÓ. Invited
panelist, The American Society of Nephrology Annual Scientific Meeting, ÒShort
Courses in the Clinical Practice of NephrologyÓ, Orlando, FL. 10/95
ÒIs a Metabolic Stone Evaluation Needed in the Age of ESWL?Ó. Invited
speaker, American Lithotripsy Society Meeting, San Antonio, TX. 10/95
ÒHistory of Inhibitors in Stone DiseaseÓ. Visiting Professor, Ohio State
University, Columbus, Ohio. 10/95 ÒUrologic Stones and Bowel DiseaseÓ.
Visiting Professor, Ohio State University, Columbus, Ohio. 7/96
ÒEvaluation of Patients with NephrolithiasisÓ. Waukesha Memorial Hospital,
Waukesha, WI, Allstaff Conference. 3/97 ÒPrevention of Kidney StonesÓ. St.
MaryÕs Hospital, Milwaukee, WI. 4/97 ÒRenal FailureÓ. Elmbrook Memorial
Hospital, Brookfield, WI, April 1997. 10/97 ÒPrevention of Acute Renal FailureÓ.
Nephrology for the Primary Care Physician. Waukesha Memorial Hospital,
Waukesha, WI. 10/98 ÒHypernatremia and Hyponatremia
– Diagnosis and ManagementÓ. Nephrology for the Primary Care Physician,
Waukesha Memorial Hospital, Waukesha, WI. 11/99 ÒChronic Renal Failure: Preventing
Progression and Preparing for the WorstÓ. Allstaff Conference, Waukesha
Memorial Hospital, Waukesha, WI. 1/30/01 ÒA Patient with ProteinuriaÓ. Medicine Grand Rounds, Univ. of
Chicago. 4/16/03 ÒKidney StonesÓ. Update in Nephrology, Crystal Lake,
IL 9/16/03 ÒHypercalcemia in a Dialysis PatientÓ. Medicine
Grand Rounds, Univ. of Chicago. 2/21/04 ÒCalcium oxalate stone formation in a rat model of
enteric hyperoxaluria.Ó ROCK Society Annual Meeting, Gainesville, FL. 4/28/04 ÒCareer Choices in NephrologyÓ, National Kidney
Foundation Clinical Meeting, Chicago, IL. 6/11/04 ÒContemporary Management of Kidney StonesÓ, Chicago
Nephrology Day, Network 9&10 Nephrology Symposium, Chicago, IL. 10/9/04 ÒA new animal model of hyperoxaluriaÓ. Invited
speaker, 7th International Workshop on Primary Hyperoxaluria, Mayo
Clinic, Rochester, MN. 5/18/05 ÒMetabolic Stone Disease: Diagnosis and ManagementÓ.
Invited speaker, Nephrology Symposium, SIU School of Medicine, Springfield,
IL. 6/3/05 ÒVascular Access UpdateÓ. Women in Nephrology Symposium: New
Interventions for Kidney Disease. University of Chicago, Chicago, IL. 3/9/06 ÒObesity, bariatric surgery, and stones.Ó NIH
Symposium on Urolithiasis, Baltimore, MD, March 9, 2006. 4/19/06 ÒCareer Choices in NephrologyÓ, National Kidney
Foundation Clinical Meeting, Chicago, IL. 11/2/06 ÒChanges in renal function and blood pressure in
stone formers.Ó First International Urolithiasis Research Symposium,
Indianapolis, IN 1/12/07 ÒA rodent model of enteric hyperoxaluria and stonesÓ
Nephrology Research Conference, University of Chicago. 5/12/07 ÒKidney Stones: Current Understanding of an Ancient
DiseaseÓ. MenÕs Health Symposium, Munster, IN. 5/22/07 ÒClinical and laboratory characteristics of patients
who transform from calcium oxalate to calcium phosphate stone formers.Ó
American Urological Society Annual Meeting, Anaheim, CA. 11/07 ÒPathophysiology of Renal Stone
DiseaseÓ. American Society of Nephrology Annual Meeting, San Francisco, CA. |